Ulcerative Colitis Pipeline Therapeutics Development, Therapeutics Assessment 2018

    117
    SHARE

    Latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Pipeline Review, H1 2018, provides an overview of the Ulcerative Colitis pipeline landscape.

    Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ulcerative Colitis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ulcerative Colitis pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 7, 14, 37, 30, 1, 49, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

    Request for a Sample Copy of this Research Report at: https://www.marketinsightsreports.com/reports/0926875167/ulcerative-colitis-pipeline-review-h1-2018/inquiry?source=tallahasseescene&Mode=01

    Ulcerative Colitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Companies Mentioned in Ulcerative Colitis are: “4D Pharma PLC, AbbVie Inc, AbGenomics International Inc, Abivax SA, Adello Biologics LLC, Akebia Therapeutics Inc, Allergan Plc, Alpha Cancer Technologies Inc, Am-Pharma BV, Amgen Inc, Aptevo Therapeutics Inc, Arena Pharmaceuticals Inc, Artelo Biosciences Inc, Atlantic Bio Sci LLC, Atlantic Healthcare Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Celgene Corp, Celltrion Inc, ChemoCentryx Inc, ChironWells GmbH, Coherus BioSciences Inc, Cosmo Pharmaceuticals NV, Dr. August Wolff GmbH & Co KG Arzneimittel, EA Pharma Co Ltd, Eli Lilly and Co, Enceladus Pharmaceuticals BV, Enterome Bioscience SA, Ferring International Center SA, Fresenius SE & Co KGaA, Galapagos NV, Genentech Inc, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, IB Pharmaceuticals Inc, iCo Therapeutics Inc., Inception Sciences Inc, InDex Pharmaceuticals Holding AB, Intas Pharmaceuticals Ltd, Istesso Ltd , Johnson & Johnson, Kaken Pharmaceutical Co Ltd , Keystone Biologics Inc, Kyowa Hakko Kirin Co Ltd, LG Chem Ltd, LIPID THERAPEUTICS GmbH, Lycera Corp, Merck & Co Inc, Miyarisan Pharmaceutical Company Ltd, Morphotek Inc, Nichi-Iko Pharmaceutical Co Ltd, Noxopharm Ltd, Ogeda SA, Oncobiologics Inc, OSE Immunotherapeutics, Palatin Technologies Inc, Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Principia Biopharma Inc, Protab Ltd, Protagonist Therapeutics Inc, Protalix BioTherapeutics Inc, Qu Biologics Inc, Re-Pharm Ltd, Rebiotix Inc, RedHill Biopharma Ltd, Reliance Life Sciences Pvt Ltd, Sandoz International GmbH, Sareum Holdings Plc, Seres Therapeutics Inc, Shire Plc, Sigmoid Pharma Ltd, Stelic Institute & Co Inc, sterna biologicals Gmbh & Co KG, Swedish Orphan Biovitrum AB, Synedgen Inc, Synergy Pharmaceuticals Inc, Synlogic Inc, Takeda Pharmaceutical Co Ltd, Theravance Biopharma Inc, Thetis Pharmaceuticals LLC, Tillotts Pharma AG, TopiVert Ltd, Torrent Pharmaceuticals Ltd, TTY Biopharm Company Ltd, UCB SA, Ventria Bioscience, Vivelix Pharmaceuticals Ltd”

    The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Browse full Report at: https://www.marketinsightsreports.com/reports/0926875167/ulcerative-colitis-pipeline-review-h1-2018?source=tallahasseescene&Mode=01

    Scope:

    1. The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis.
      2. The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
      3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
      4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
      5. The pipeline guide reviews key companies involved in Ulcerative Colitis therapeutics and enlists all their major and minor projects.
      6. The pipeline guide evaluates Ulcerative Colitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
      7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
      8. The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis

    Reasons to buy this Report:

    1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    2. Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis.
    Classify potential new clients or partners in the target demographic.
    3. Develop tactical initiatives by understanding the focus areas of leading companies.
    4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    5. Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics.
    6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Important Points Covered In Table of Content are:

    Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.